Published in final edited form as:

Brain Stimul. 2019 ; 12(2): 371–373. doi:10.1016/j.brs.2018.11.010.

Stability of the Cardiovascular Response during Single-pulse TMS in Perinatal Stroke

Manda L. Keller-Ross, PhD, DPT^{1,2}, Daniel P. Chantigian, MS¹, Mo Chen, PhD³, Tonya L. Rich, PhD¹, Chao-Ying Chen, PhD^{2,4}, Bernadette T. Gillick, PT, PhD^{1,2}

¹Division of Rehabilitation Science, Medical School, University of Minnesota, Minneapolis, MN

²Division of Physical Therapy, Medical School, University of Minnesota, Minneapolis, MN.

³Institute for Engineering and Medicine, University of Minnesota, Minneapolis, MN

⁴Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong

To the Editor:

Serious adverse events of syncope have been reported with single pulse transcranial magnetic stimulation (sp-TMS) in both healthy adults and adolescents post stroke [3, 5, 7–9]. Despite these reports, the physiological mechanisms leading to syncope during sp-TMS administration are not clearly understood. A syncopal event is classically identified by a sudden, large reduction in blood supply to neural tissue “cerebral hypoperfusion” to ultimately cause a loss of consciousness [2]. Common symptoms preceding syncope include lightheadedness, nausea, diaphoresis, and/or visual changes. Syncopal events may occur via an irregular autonomic nervous system (ANS) response to emotional or administered stimuli, which is commonly known as neurocardiogenic syncope [2, 4]. Neurocardiogenic syncope can result from transient mean arterial pressure (MAP) and heart rate (HR) changes in response to precipitating factors such as anxiety in combination with a mildly noxious, novel stimulus [4]. Although literature is sparse, children with perinatal stroke appear to be at an additional increased risk for autonomic dysfunction [1] and autonomic immaturity in typically-developing pediatric populations increases the risk for neurocardiogenic syncope [4]. We aimed to determine if sp-TMS caused immediate cardiovascular changes in children and adolescents with congenital hemiparesis due to perinatal stroke.

Seven males (12±4 yrs, average±sd) and eight females (14±5 yrs) completed an experimental session as part of a larger clinical trial (). A 70-mm-diameter Magstim figure-of-eight coil (Magstim, Whitland, U.K.) with a Magstim 200² unit delivered stimulation for

Correspondence and Reprint Requests to: Manda L. Keller-Ross, Ph.D., DPT, Division of Physical Therapy and Rehabilitation Science, Medical School, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN 55116, kell0529@umn.edu, Phone: 612-625-3175, Fax: 612-625-4274.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CONFLICT OF INTEREST

There are no conflicts of interest to disclose.

sp-TMS assessment to determine resting motor threshold of the primary motor cortex (M1) ($59 \pm 13\%$ of maximum stimulator output, $\text{avg} \pm \text{SD}$, range: 35–75%). Continuous MAP (NIBP, AD Instruments, Colorado Springs, CO) and HR (3-lead electrocardiogram) were measured during pre-stimulation rest and throughout sp-TMS administration.

Average MAP ($p=0.48$, Figure 1A) and HR ($p=0.10$, Figure 1B) did not change from baseline during the initial five or last five pulses of sp-TMS. Analysis of the six seconds following each sp-TMS to M1 indicated that MAP increased during the initial five stimulations, ($p=0.03$, Figure 1C), but not during the final five stimulations ($p=0.86$, Figure 1D). HR increased during the six seconds following the initial five sp-TMS stimulations ($p=0.01$, Figure 1E) and final five stimulations ($p<0.01$, Figure 1F). Five of the fifteen participants had been previously exposed to sp-TMS; however, previous exposure did not influence MAP or HR responses ($p>0.05$).

Adverse events were monitored during and following sp-TMS. There were two reports of headache and one report of dizziness immediately following sp-TMS, which resolved within one hour. The investigator determined that these reports of symptoms were possibly related to TMS. In addition, at completion of the study, one male, who was previously exposed to sp-TMS, reported sleepiness and experienced a near syncopal event. Because this was at the completion of his study, equipment used for continuous monitoring of MAP and HR had been removed. We therefore measured his blood pressure (BP) and HR manually during the event (BP: 80/50 mmHg; HR: 80 bpm). As a component of adverse event management, the study team reclined the participant, elevated his legs, and aroused the participant by engaging him in conversation. After ~3 minutes, his manual BP was 100/70 mmHg, and symptoms had resolved. Throughout sp-TMS administration, we observed minimal alterations in MAP or HR. In fact, he did not demonstrate a fluctuation of MAP greater than 10mmHg from baseline and his average BP was 114/62 mmHg and HR was 75 bpm throughout sp-TMS testing. The medical monitor for this study reviewed all participant responses, including the responses from this participant, approved of the management, and declared no safety concerns or need for further medical management.

The findings from this study suggest that sp-TMS likely does not disrupt autonomic nervous system function to alter MAP and HR and increase risk of syncope in a pediatric cohort with perinatal stroke. There was an increase in both HR and MAP during the six seconds following each TMS stimuli, but as these changes were small, on average -1 to $+3$ bpm, the clinical relevance of this is unclear. The delivery of sp-TMS to M1 has the potential to alter the autonomic nervous system through connections to the anterior hypothalamus and the nucleus tractus solitarius of the pons/medulla [6]. Indeed, if sp-TMS directly altered autonomic function to cause syncope, we might expect large reductions in MAP and/or HR immediately following TMS pulses. The male participant who experienced a near syncopal event had stable MAP/HR throughout the duration of the sp-TMS testing. We, therefore feel confident that sp-TMS did not directly influence his autonomic nervous system, altering MAP or HR to lead to his near syncopal event. As this participant was previously exposed to sp-TMS it lessens the likelihood of a novel stimulus/environment to be the cause of his symptoms. Therefore, the etiology of the near syncopal event in this participant is unclear. However, evidence suggests that autonomic immaturity may place adolescents at a greater

risk for neurocardiogenic syncope and a sex difference in cerebral autoregulation may pose an additional risk for young males [10]. In addition, two previously reported pediatric syncopal events reported in children post stroke were males [8]. Therefore, it is possible that the combination of being an adolescent post-stroke and male increased this participant's risk for neurocardiogenic syncope leading to a near syncopal event.

In conclusion, results from this study indicate that MAP and HR were stable during sp-TMS administration in this cohort of children and adolescents with perinatal stroke. To ensure safety in participants during TMS administration, future studies should monitor and report cardiovascular responses.

ACKNOWLEDGMENTS

This work was supported by the National Institutes of Health (NIH) Kennedy Shriver National Institutes of Child Health and Development K01 Award (HD078484–01A1), the Cerebral Palsy Foundation, The Foundation for Physical Therapy Magistro Family Grant and Minnesota's Discovery, Research, and Innovation Economy (MnDRIVE). The project was also supported in part by Award UL1 TR000114 and KL2 TR000113. The results of this study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation.

Bibliography

- [1]. Amichai T, Katz-Leurer M, Heart rate variability in children with cerebral palsy: review of the literature and meta-analysis, *NeuroRehabilitation* 35 (2014) 113–122. [PubMed: 24990007]
- [2]. da Silva RM, Syncope: epidemiology, etiology, and prognosis, *Front Physiol* 5 (2014) 471. [PubMed: 25538626]
- [3]. Gillick BT, Rich T, Chen M, Meekins GD, Case report of vasovagal syncope associated with single pulse transcranial magnetic stimulation in a healthy adult participant, *BMC Neurol* 15 (2015) 248. [PubMed: 26627895]
- [4]. Grubb BP, Neurocardiogenic syncope and related disorders of orthostatic intolerance, *Circulation* 111 (2005) 2997–3006. [PubMed: 15939833]
- [5]. Hadar AA, Makris S, Yarrow K, Single-pulse TMS related syncopal spell in a healthy subject, *Brain Stimul* 5 (2012) 652–653. [PubMed: 21930450]
- [6]. Hall JE, *Neural Regulation of the Circulation and Rapid Control of Arterial Pressure* Guyton and Hall Textbook of Medical Physiology, 13th Edition, Elsevier, Philadelphia, PA: Elsevier, 2016, pp. 215–225.
- [7]. Kesar TM, McDonald HS, Eicholtz SP, Borich MR, Case Report of Syncope During a Single Pulse Transcranial Magnetic Stimulation Experiment in a Healthy Adult Participant, *Brain Stimul* 9 (2016) 471–472. [PubMed: 27050115]
- [8]. Kirton A, Deveber G, Gunraj C, Chen R, Neurocardiogenic syncope complicating pediatric transcranial magnetic stimulation, *Pediatr Neurol* 39 (2008) 196–197. [PubMed: 18725065]
- [9]. Sczesny-Kaiser M, Höffken O, Tegenthoff M, Schwenkreis P, Convulsive syncope after single-pulse TMS, *Brain Stimul* 6 (2013) 830.
- [10]. Vavilala MS, Kincaid MS, Muangman SL, Suz P, Rozet I, Lam AM, Gender differences in cerebral blood flow velocity and autoregulation between the anterior and posterior circulations in healthy children, *Pediatr Res* 58 (2005) 574–578. [PubMed: 16148076]

Figure 1.

Averaged mean arterial pressure (MAP) (**A**) and heart rate (**B**) during baseline, the initial five and last five stimulations of sp-TMS during RMT determination, and recovery. Second-by-second averages of MAP and heart rate during the initial (**C** & **E**, respectively) and last five stimulations (**D** & **F**, respectively). An average of second-by-second response is indicated by the grey symbols and all other symbols indicate individual responses to sp-TMS. Closed symbols indicate individuals that had previously been exposed to TMS (n=5).